Canaccord Adams
http://www.canaccordadams.com/default.htmCanaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, their 225 professionals seek out emerging opportunities in their key sectors - Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in nine offices internationally, their experienced team generates focused, actionable ideas that identify opportunity and facilitate growth.
-
Canaccord Adams Upgrades Amylin Pharmaceuticals (AMLN) to Hold; Competitors on the Way and Safety Issues May Continue to Weigh on Shares
-
Canaccord Adams Reiterates Sell on Amylin (AMLN)
-
Wall Street Throws In the Towel On Amylin (AMLN) Following New Byetta Patient Deaths
-
Canaccord Adams Lowers Price Target on Amylin (AMLN) to $20
-
Canaccord Reiterates Sell on Amylin (AMLN) Following Byetta Issues

